Document Detail


Glycogen Synthase Kinase-3 as a Therapeutic Target for Cognitive Dysfunction in Neuropsychiatric Disorders.
MedLine Citation:
PMID:  25380674     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) is involved in a broad range of cellular processes including cell proliferation, apoptosis and inflammation. It is now also increasingly acknowledged as having a role to play in cognitive-related processes such as neurogenesis, synaptic plasticity and neural cell survival. Cognitive impairment represents a major debilitating feature of many neurodegenerative and psychiatric disorders, including Alzheimer's disease, mood disorders, schizophrenia and fragile X syndrome, as well as being a result of traumatic brain injury or cranial irradiation. Accordingly, GSK-3 has been identified as an important therapeutic target for cognitive impairment, and recent preclinical studies have yielded important evidence demonstrating that GSK-3 inhibitors may be useful therapeutic interventions for restoring cognitive function in some of these brain disorders. The current review summarises the role of GSK-3 as a regulator of cognitive-dependent functions, examines current preclinical and clinical evidence of the potential of GSK-3 inhibitors as therapeutic agents for cognitive impairments in neuropsychiatric disorders, and offers some insight into the current obstacles that are impeding the clinical use of selective GSK-3 inhibitors in the treatment of cognitive impairment.
Authors:
Olivia O'Leary; Yvonne Nolan
Related Documents :
20178634 - Regulation and dysregulation of immunoglobulin e: a molecular and clinical perspective.
21075284 - Pharmacologic induction of fetal hemoglobin production.
20382044 - Lichen planus pemphigoides, a possible example of epitope spreading.
7032424 - Coexistence of localized bullous pemphigoid, morphea, and subcorneal pustulosis.
10086634 - Challenging problems presenting as constipation.
21963414 - Analyses related to the development of dsm-5 criteria for substance use related disorde...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-8
Journal Detail:
Title:  CNS drugs     Volume:  -     ISSN:  1172-7047     ISO Abbreviation:  CNS Drugs     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-11-8     Completed Date:  -     Revised Date:  2014-11-9    
Medline Journal Info:
Nlm Unique ID:  9431220     Medline TA:  CNS Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Malariometric indices from Iganga, Uganda: baseline characterization in preparation of GMZ2 vaccine ...
Next Document:  Acute exercise increases resistance to oxidative stress in young but not older adults.